Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Dec. 12, 2019 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
Nov. 19, 2020 |
Dec. 13, 2019 |
|
| Research and development expenses | $ 4,621,255 | $ 3,336,225 | $ 10,343,451 | $ 10,833,345 | ||||
| Revenue | $ 95,833 | 33,333 | $ 95,833 | |||||
| Genentech [Member] | ||||||||
| Revenue | 33,000 | |||||||
| Award Agreement [Member] | ||||||||
| Research and development expenses | 588,000 | 1,558,000 | ||||||
| Award Agreement [Member] | Prepaid Expenses and Other Current Assets [Member] | ||||||||
| Account receivable | 980,000 | 980,000 | ||||||
| Award Agreement [Member] | Accrued Expense And Other Current Liabilities [Member] | ||||||||
| Deferred liability | $ 1,199,000 | $ 1,199,000 | $ 650,000 | |||||
| Related receivable | 577,000 | |||||||
| Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | ||||||||
| Therapeutics development award | $ 4,200,000 | |||||||
| Proceeds from award | $ 484,249 | |||||||
| Genentech Feasibility Study Agreement [Member] | Genentech [Member] | ||||||||
| Agreement description | Genentech shall pay the Company a total of $100 thousand for developing oral formulations of three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. | |||||||
| Deferred revenue | $ 100,000 | |||||||
| X | ||||||||||
- Definition Agreement description. No definition available.
|
| X | ||||||||||
- Definition Proceeds from award. No definition available.
|
| X | ||||||||||
- Definition Therapeutics development award. No definition available.
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|